TOBIT: Duration of Dual Antiretroviral Therapy in Virologically Suppressed People Living With HIV and Factors Associated With Switching to Tritherapy : a Real-life Cohort

Sponsor

Tourcoing Hospital (Other)

Overall Status

Completed

CT.gov ID

NCT06107140

Collaborator

(none)

580

Enrollment

Location

147.9

Actual Duration (Months)

3.9

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

HIV infection requires lifelong continuous antiretroviral (ARV) treatment. The efficacy of current ARV treatments makes it possible to propose strategies for reducing the cumulative exposure to ARVs, side effects and costs. And so improve the quality of life of people living with HIV (PLHIV). However, in the real world, less regular adherence to treatment, more heavily pre-treated patients and resistance to treatment make these dual therapies prescribed beyond the strict framework of clinical trials. This can lead to undesirable side effects. From the perspective of personalized medicine, it seems to be important to determine which patients are receiving dual ARV therapy, and which patients remain on it for a long time. Identifying prognostic factors would enable us to adapt therapeutic management.

Condition or Disease	Intervention/Treatment	Phase
HIV Infections	Other: dual therapy

Study Design

Study Type:

Observational

Actual Enrollment :

580 participants

Observational Model:

Cohort

Time Perspective:

Retrospective

Official Title:

Duration of Dual Antiretroviral Therapy in Virologically Suppressed People Living With HIV and Factors Associated With Switching to Tritherapy : a Real-life Cohort

Actual Study Start Date :

Jan 1, 2011

Actual Primary Completion Date :

May 1, 2023

Actual Study Completion Date :

May 1, 2023

Outcome Measures

Primary Outcome Measures

therapeutic switch [5 years]
Proportion of patients switching from dual to triple therapy

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

hiv patient
viral load < 50copies/ml
patient treated with dual therapy
patients with hospital follow-up between 2011 and 2023

Exclusion Criteria:

adults under legal protection
underage

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Centre Hospitalier DRON	Tourcoing		France	59208

Sponsors and Collaborators

Tourcoing Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Tourcoing Hospital

ClinicalTrials.gov Identifier:

NCT06107140

Other Study ID Numbers:

CHT/URC/2023/13

First Posted:

Oct 30, 2023

Last Update Posted:

Nov 1, 2023

Last Verified:

Oct 1, 2023

Individual Participant Data (IPD) Sharing Statement:

Plan to Share IPD:

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Keywords provided by Tourcoing Hospital

epidemiology

Additional relevant MeSH terms:

HIV Infections

Study Results

No Results Posted as of Nov 1, 2023